Preclinical Validation of Therapeutics

RxGen seeks to form research relationships with companies that would strategically benefit from access to our expertise and resources for the preclinical validation of promising therapeutic candidates, including small molecule drugs, RNAi, gene therapies, antibodies, peptides, cell replacement technologies, or medical devices. Drawing on our experience from prior service collaborations with other biotechnology and pharmaceutical companies, we will work with you to design and structure a cost-effective solution to advancing your development plan from concept to final report. Please contact us to see how we can meet your needs.

Custom Services

RxGen has a demonstrated ability to work with outside parties to develop new models of disease or implement new approaches to evaluating therapeutic efficacy or toxicity. Our access to primates combined with nearly 30 years of experience in primate research ensures that we have the ability to tackle even the most challenging projects. Our current management team and research staff possesses a broad range of skills and knowledge beyond those listed here that can further suit your specific needs. If you feel that your drug development program could potentially benefit from working with RxGen, please contact us.

Co-Development & Investment Opportunities

In addition to contract research services, RxGen is open to exploring creative financing, partnership, and/or joint venture structures with companies that are developing, or otherwise own intellectual property rights to a promising therapeutic agent(s), diagnostic(s), and/or medical technology that require significant investments in preclinical studies. If you feel that a research and commercialization partnership between RxGen and your organization would represent such a synergy, please contact Christopher Stanley at (512) 897-7020 or email cstanley@rx-gen.com.